2012
DOI: 10.1007/s13665-012-0039-4
|View full text |Cite
|
Sign up to set email alerts
|

Advanced non-squamous non-small-cell lung cancer: who and when should be biologically screened today? Tomorrow?

Abstract: There is a need for identification of prognostic and/or predictive biomarkers to improve the choice of therapeutic strategies for patients diagnosed with advanced nonsquamous NSCLC. Only two predictive biomarkers have been validated: EGFR mutations and EML4-ALK translocations. These markers can be used to predict the response to targeted therapy (erlotinib and gefitinib or crizotinib). Several emerging biomarkers are being studied in ongoing clinical trials to predict the response of new targeted therapy or re… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2019
2019
2019
2019

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 34 publications
(36 reference statements)
0
1
0
Order By: Relevance
“…To date, lung cancer remains as the leading type of cancer according to its incidence and mortality rate worldwide (1). It comprises two main histological subtypes, non-small cell lung cancer (NSCLC) and small-cell lung cancer (SCLC).…”
Section: Introductionmentioning
confidence: 99%
“…To date, lung cancer remains as the leading type of cancer according to its incidence and mortality rate worldwide (1). It comprises two main histological subtypes, non-small cell lung cancer (NSCLC) and small-cell lung cancer (SCLC).…”
Section: Introductionmentioning
confidence: 99%